Loading...
Loading...
NRIX| Name | Value |
|---|---|
| Revenues | 30.7M |
| Cost of Revenue | 3.3M |
| Gross Profit | 27.3M |
| Operating Expense | 57.4M |
| Operating I/L | -26.8M |
| Other Income/Expense | 2.5M |
| Interest Income | 2.5M |
| Pretax | -24.3M |
| Income Tax Expense | -2.5M |
| Net Income/Loss | -21.8M |
Nurix Therapeutics, Inc. is a biopharmaceutical company specializing in the development and commercialization of small molecule therapies for cancer and immune disorders. The company's product pipeline includes NX-2127 and NX-5948, both orally available Bruton's tyrosine kinase (BTK) degraders for relapsed or refractory B-cell malignancies and autoimmune diseases, as well as NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. Additionally, they are developing NX-0255 and DeTIL-0255 for adoptive T-cell therapy and gynecologic cancer treatment, respectively. Nurix Therapeutics generates revenue through the discovery, development, and commercialization of these innovative therapies.
